Quality of life in schizophrenia on conventional versus a typical antipsychotic medication: A comparative cross-sectional study

International Journal of Social Psychiatry

Volumn 53, Issue 2, 2007, Pages 99-107

  Mortimer, Ann M ^a   Al Agib, Ahmed Omar Ahmed ^b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b Clinical Psychology Service for Older People   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COMORBIDITY; COMPARATIVE STUDY; CONFOUNDING VARIABLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FACTORIAL ANALYSIS; FEMALE; HOSPITALIZATION; HUMAN; INDEPENDENCE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SICKNESS IMPACT PROFILE; STATISTICAL MODEL; SUBSTANCE ABUSE; TREATMENT RESPONSE;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; ANTIPSYCHOTIC AGENTS; ATTITUDE TO HEALTH; CHRONIC DISEASE; COMORBIDITY; CROSS-SECTIONAL STUDIES; DELUSIONS; FEMALE; GREAT BRITAIN; HUMANS; LENGTH OF STAY; LINEAR MODELS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SICKNESS IMPACT PROFILE; STATISTICS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 33847789364     PISSN: 00207640     EISSN: 17412854     Source Type: Journal    
DOI: 10.1177/0020764006075000     Document Type: Article

References (24)

1. ANDERSON, C., CAKOS, M. & MAILMAN, R. (1998) Emerging roles for novel antipsychotic medications in the treatment of schizophrenia. Psychiatric Clinical North America, 21, 151-179.
2. AWAD, A.G. & VORUGANTI, L.N.P. (1999) Quality of life and new antipsychotics in schizophrenia: Are patients better off? International Journal of Social Psychiatry, 45, 268-275.
3. AWAD, A.G., VORUGANTI, L.N.P. & HESLEGRAVE, R.J. (1995) The aims of antipsychotic medication. CNS Drugs, 4, 8-16.
4. BAILLARGEON, J. & CONTRERAS, S.A. (2001) Antipsychotic prescribing patterns in the Texas prison system. Journal of the American Academy of Psychiatry and the Law, 29, 48-53.
5. CORRIGAN, P.W., REINKE, R., LANDSBERGER, S.A., et al. (2003) The effect of atypical antipsychotic medications on psychosocial outcomes. Schizophrenia Research, 63, 97-101.
6. COVELL, N.H., JACKSON, C.T., EVANS, A.C., et al. (2002) Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medication and prescribing styles. Schizophrenia Bulletin, 28, 17-29.
7. DEWA, C.S., REMINGTON, G., HERRMANN, N., et al. (2002) How much are atypical antipsychotics being used, and do they reach the populations who need them? A Canadian experience. Clinical Therapeutics, 24, 1466-1476.
8. ENDICOTT, J., SPITZER, R.L. & FLEISS, J.L. (1976) The global assessment scale: A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry, 33, 766-771.
9. HOGAN, T., AWAD, A. & EASTWOOD, R. (1983) A self report scale, predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychological Medicine, 13, 177-183.
10. KAROW, A. & NABER, D. (2002) Subjective wellbeing and quality of life under atypical antipsychotic treatment. Psychopharmacology, 162, 3-10.
11. KILIAN, R., DIETRICH, S., TOUMI, M., et al. (2004) Quality of life in persons with schizophrenia in out-patient treatment with first- or second-generation antipsychotics. Acta Psychiatrica Scandanavica, 110, 108-118.
12. LEHMAN, W. (1983) The well-being of chronic mental patients: Assessing their quality of life. Archives of General Psychiatry, 40, 369-373.
13. LIEBERMAN, J.A. (1996) A typical antipsychotic drugs as a first line treatment of schizophrenia: Rationale and hypothesis. Journal of Clinical Psychiatry, 57, 68-71.
14. LIPEROTI, R., MOR, V., LAPANE, H.L., et al. (2003) The use of antipsychotics in nursing homes. Journal of Clinical Psychiatry, 64, 1106-1112.
15. LUO, R.D., BELLETTI, D.A., TRAN, D., et al. (2002) National prescribing patterns in the mangement of extrapyramidal symptoms among patients with schizophrenia. International Journal of Psychiatry in Medicine, 32, 261-269.
16. MARDER, S.R., ESSOCK, S.M., MILLER, A.L., et al. (2002) The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophrenia Bulletin, 28, 5-16.
17. NABER, D., KAROW, A. & LAMBERT, M. (2002) Psychological outcomes in patients with schizophrenia: Quality of life and reintegration. Current Opinion in Psychiatry, 15, 31-36.
18. POMERANTZ, J.M. (2002) Quality of life in schizophrenia and drug formulary restriction. Drug Benefit Trends, 14, 32-34.
19. RITSNER, M. & KURS, R. (2002) Impact of antipsychotic agents and their side effects on the quality of life in schizophrenia. Expert Reviews in Pharmacoeconomic Outcome Research, 2, 347-356.
20. RITSNER, M., PONIZOUSKY, A. & ENDICOTT, J. (2002) The impact of side effects of antipsychotic agents on life satisfaction of schizophrenia patients. European Neuropsychopharmacology, 12, 31-38.
21. ROTHBARD, A., KUNO, E. & FOLEY, K. (2003) Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophrenia Bulletin, 29, 531-540.
22. VORUGANTI, L.N.P., CORTESE, L. & OYEWUMI, Z. (2000) Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side effect profile and impact on quality of life. Schizophrenia Research, 43, 135-145.
23. VORUGANTI, L.N.P., CORTESE, L. & OYEWUMI, Z. (2002) Switching from conventional to novel anti-psychotic drugs: A prospective naturalistic study. Schizophrenia Research, 57, 201-208.
24. WILKINSON, G., HESDON, B. & WILD, D. (2000) Self report quality of life measure for people with schizophrenia: The SQLS. British Journal of Psychiatry, 177, 42-46.